...
首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Phase 1 Results from a Phase 1/2 Study to Assess the Safety, Tolerability and Recommended Phase 2 Dose (RP2D) of Brentuximab Vedotin Plus Doxorubicin, Vinblastine and Dacarbazine (A plus AVD) in Pediatric Patients (Pts) with Advanced Stage Newly Diagnosed Classical Hodgkin Lymphoma (cHL)
【24h】

Phase 1 Results from a Phase 1/2 Study to Assess the Safety, Tolerability and Recommended Phase 2 Dose (RP2D) of Brentuximab Vedotin Plus Doxorubicin, Vinblastine and Dacarbazine (A plus AVD) in Pediatric Patients (Pts) with Advanced Stage Newly Diagnosed Classical Hodgkin Lymphoma (cHL)

机译:1/2期的第1阶段结果,以评估小儿患者(PTS)中布伦克西非葡萄球菌,长霉素和达卡巴嗪(A加AVD)的安全性,耐受性和推荐2剂量(RP2D),具有新诊断的经典的晚期阶段 Hodgkin淋巴瘤(CHL)

获取原文
获取原文并翻译 | 示例
           

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号